Article
Biochemical Research Methods
Ziyang Ma, Jeongyoun Ahn
Summary: The study proposed a new method that can reveal the ordinal structure of classes in high-dimensional data and applied it to predict the response of multiple myeloma patients to different drugs. Comparative analysis with existing methods showed that the proposed method achieves competitive predictive performance while maintaining the intrinsic ordinal structure of classes.
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Jingjing Wang, Xu Zhu, Lin Dang, Hongmei Jiang, Ying Xie, Xin Li, Jing Guo, Yixuan Wang, Ziyi Peng, Mengqi Wang, Jingya Wang, Sheng Wang, Qian Li, Yafei Wang, Qiang Wang, Lingqun Ye, Lirong Zhang, Zhiqiang Liu
Summary: The t(4;14) chromosomal translocation drives high expression of NSD2 and plays important roles in MM evolution and progression. HRP2 downregulation is associated with poor response and worse outcomes in PIs treatment, and its suppression promotes cell survival and restricts ER stress by increasing H3K27me3 levels.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Oncology
Romika Kumari, Muntasir Mamun Majumder, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman
Summary: This study evaluated the biological significance of esterase expression in multiple myeloma (MM) by analyzing gene expression profiling and genomic variants in patients with newly diagnosed MM (NDMM) or relapsed/refractory MM (RRMM). High or low expression of specific esterases in MM, such as UCHL5, SIAE, ESD, PAFAH1B3, PNPLA4, and PON1, were significantly altered as patients progressed from NDMM to RRMM. Certain esterases, like OVCA2, PAFAH1B3, SIAE, USP4, and PCED1B, were identified as poor prognostic markers, suggesting their potential role in myeloma biology.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Rosalie Griffin, Heidi A. Hanson, Brian J. Avery, Michael J. Madsen, Douglas W. Sborov, Nicola J. Camp
Summary: This study presents an approach called SPECTRA, which uses transcriptome data to predict clinical outcomes in multiple myeloma patients. The derived quantitative variables can provide insights into tumor differences and are associated with clinical and expression risk factors.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Review
Oncology
Hong Ding, Juan Xu, Zhimei Lin, Jingcao Huang, Fangfang Wang, Yan Yang, Yushan Cui, Hongmei Luo, Yuhan Gao, Xinyu Zhai, Weicui Pang, Li Zhang, Yuhuan Zheng
Summary: MRD in MM plays a critical role in disease pathogenesis, demonstrating unique cytogenetic aberrations and gene expression profiles. Different risk MM exhibit diverse MRD features, with clonal evaluation potentially occurring at the MRD stage. MM MRD before and after treatment shows distinct differences.
BIOMARKER RESEARCH
(2021)
Article
Hematology
Fabio Malavasi, Angelo C. Faini, Fabio Morandi, Barbara Castella, Danny Incarnato, Salvatore Oliviero, Alberto L. Horenstein, Massimo Massaia, Niels W. C. J. van de Donk, Paul G. Richardson
Summary: This study explored the multiple functions of CD38 and the effects of therapeutic antibodies on membrane dynamics and gene expression in multiple myeloma cells. The exposure to anti-CD38 antibodies resulted in changes in metabolism-related and cell cycle-related genes, as well as modulation of microRNA expression. Microvesicles released from the antibody-exposed cells showed alterations in both protein expression and microRNA levels, suggesting a potential role in intercellular signaling and immune response modulation. The findings provide insights on the potential mechanisms for enhancing the efficacy of anti-CD38 therapeutic antibodies.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Maximilian Merz, Almuth Maria Anni Merz, Jie Wang, Lei Wei, Qiang Hu, Nicholas Hutson, Cherie Rondeau, Kimberly Celotto, Ahmed Belal, Ronald Alberico, AnneMarie W. Block, Hemn Mohammadpour, Paul K. Wallace, Joseph Tario, Jesse Luce, Sean T. Glenn, Prashant Singh, Megan M. Herr, Theresa Hahn, Mehmet Samur, Nikhil Munshi, Song Liu, Philip L. McCarthy, Jens Hillengass
Summary: This study characterizes osteolytic lesions (OL) in multiple myeloma patients using single-cell RNA sequencing (scRNA-seq), revealing specifically regulated genes in OL compared to random bone marrow samples, as well as their response to induction therapy.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Toru Masuda, Shojiro Haji, Yasuhiro Nakashima, Mariko Tsuda, Daisaku Kimura, Akiko Takamatsu, Norifusa Iwahashi, Hironobu Umakoshi, Motoaki Shiratsuchi, Chie Kikutake, Mikita Suyama, Yasuyuki Ohkawa, Yoshihiro Ogawa
Summary: In this study, longitudinal single-cell transcriptome sequencing was performed on multiple myeloma (MM) cells from a patient with relapsed MM. The researchers observed dynamic changes in MM cells in response to anti-myeloma drugs and identified a drug-response gene, PELI2. Their integrated strategy provided new insights into the clonal dynamics of MM and identification of drug-response genes.
Article
Oncology
Luis V. Valcarcel, Ane Amundarain, Marta Kulis, Stella Charalampopoulou, Ari Melnick, Jesus San Miguel, Jose Martin-Subero, Francisco J. Planes, Xabier Agirre, Felipe Prosper
Summary: This study identified active promoters and alternative active promoters in different B cell subpopulations and MM patient samples, showing specific expression patterns for each subpopulation. The expression from some alternative promoters was associated with lower progression-free and overall survival in MM patients, independently of genetic alterations. These findings suggest that cancer-specific alternative active promoters could serve as new transcriptomic features for prognostic stratification in MM patients.
Article
Biochemical Research Methods
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Summary: The study identified expression patterns of ICGs and their correlations with patient response to immune checkpoint blockade therapy, providing insights into the mechanisms of ICGs in anticancer treatments. A model using ICG expression features showed robust performance in predicting patient responses and outperformed other mRNA-based predictors.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Hematology
Taiga Nishihori, James E. Hoffman, Anne Huff, Gurpreet S. Kapoor, Ioanna Eleftheriadou, Stefan Zajic, Alisa Urbano, Sunil Suchindran, Michael Chisamore, Jimson W. D'Souza, Thomas Faitg, Aaron P. Rapoport
Summary: This pilot study evaluated the safety and efficacy of letetresgene autoleucel (lete-cel) alone or in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. The results showed transient antitumor activity and manageable safety profile of letetresgene autoleucel in these patients.
Article
Oncology
Juho J. Miettinen, Romika Kumari, Gunnhildur Asta Traustadottir, Maiju-Emilia Huppunen, Philipp Sergeev, Muntasir M. Majumder, Alexander Schepsky, Thorarinn Gudjonsson, Juha Lievonen, Despina Bazou, Paul Dowling, Peter O'Gorman, Ana Slipicevic, Pekka Anttila, Raija Silvennoinen, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman
Summary: The study identified differential expression of aminopeptidases associated with survival in multiple myeloma patients, highlighted the effectiveness of melflufen in relapsed/refractory cases, and demonstrated the role of specific aminopeptidases in activating the drug.
Article
Oncology
Davine Hofste Op Bruinink, Rowan Kuiper, Mark van Duin, Tom Cupedo, Vincent H. J. van der Velden, Remco Hoogenboezem, Bronno van der Holt, H. Berna Beverloo, Erik T. Valent, Michael Vermeulen, Francesca Gay, Annemiek Broijl, Herve Avet-Loiseau, Nikhil C. Munshi, Pellegrino Musto, Philippe Moreau, Sonja Zweegman, Niels W. C. J. van de Donk, Pieter Sonneveld
Summary: This study successfully identified pPCL and classified 10% of NDMM tumors as PCL-like by constructing a transcriptomic classifier, indicating the presence of a specific transcriptome in high-risk NDMM patients. The PCL-like status showed significant prognostic value in outcome assessment, potentially improving the accuracy of current risk models.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Sen Chen, Jun Ran, Zhouqian Fan, Mingyou Liu, Liang Wu, Qiude Li, Jian Peng, Zuquan Hu
Summary: This study revealed that RNH1 has clinical value in bladder cancer therapy, as low expression of RNH1 is associated with invasion and metastasis of bladder cancer, as well as immune activation and tumor immune response. Moreover, high expression of RNH1 is significantly linked with therapeutic signaling pathways and drug targets in bladder cancer. Therefore, RNH1 could provide new insights into invasion of bladder cancer and predict immunotherapy response.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Michele Cavo, Jesus San-Miguel, Saad Z. Usmani, Katja Weisel, Meletios A. Dimopoulos, Herve Avet-Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vania Hungria, Philippe Moreau, Maria-Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Facon, Shaji Kumar, Niels W. C. J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec, Rachel Kobos, Steven Sun, Mia Qi, Nikhil Munshi
Summary: In this study, we explored the impact of minimal residual disease (MRD) on relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). The results showed that achieving complete response or better (>= CR) and MRD negativity were associated with improved progression-free survival (PFS) in both RRMM and TIE NDMM patients, regardless of the type of therapy or disease setting.
Letter
Hematology
Thomas Gastinne, Amandine Le Bourgeois, Marianne Coste-Burel, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Berthe-Marie Imbert, Thomas Drumel, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Benoit Tessoulin, Maxime Jullien, Sophie Vanthygem, Marie C. Bene, Philippe Moreau, Steven Le Gouill, Patrice Chevallier
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Hematology
Nicholas Stong, Maria Ortiz-Estevez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta
Summary: Although t(4;14) translocation is considered high risk in NDMM, only a minority of patients with t(4;14) have poor outcomes. We conducted a large-scale WGS and RNA sequencing analysis on t(4;14) and non-t(4;14) NDMM patients, and identified biomarkers associated with poor outcome, including translocation breakpoints in the NSD2 gene and expression of IgH-NSD2 fusion transcripts. The location of DNA breakpoints also significantly impacts overall survival.
Article
Oncology
Alejandra Mendez Romero, Bronno van der Holt, Francois E. J. A. Willemssen, Rob A. de Man, Ben J. M. Heijmen, Steven Habraken, Henrike Westerveld, Otto M. van Delden, Heinz-Josef Klumpen, Eric T. T. L. Tjwa, Petra M. Braam, Sjoerd F. M. Jenniskens, Thomas Vanwolleghem, Reinhilde Weytjens, Olivier d'Archambeau, Judith de Vos-Geelen, Jeroen Buijsen, Christiaan van der Leij, Wilhelm den Toom, Dave Sprengers, Jan N. M. Ijzermans, Adriaan Moelker
Summary: In this multicenter randomized trial, the efficacy of transarterial chemoembolization delivered with drug eluting beads (TACE-DEB) was compared with stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC). The study found that SBRT showed higher local antitumoral activity than TACE-DEB, without detrimental effects on overall survival (OS), toxicity, and quality of life (QoL).
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Hematology
Mohamad Mohty, Herve Avet-Loiseau, Florent Malard, Jean-Luc Harousseau
Summary: Multiple myeloma is an incurable disease with high relapse rates. Deeper and more sustainable responses have been shown to improve outcomes and potentially lead to a cure. Current definitions of disease response are suboptimal, and the aim should be to measure measurable residual disease negativity. Advanced techniques have allowed the detection of a single myeloma cell among a million healthy cells.
Article
Oncology
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polee, H. C. van Santvoort, J. de Vos Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, Dutch Pancreatic Cancer Grp
Summary: This study aims to compare the effectiveness of adjuvant chemotherapy after surgery and neoadjuvant chemotherapy followed by surgery. The objective is to find the optimal approach for the treatment of resectable pancreatic cancer.
Article
Oncology
Niels W. C. J. van de Donk, Monique C. Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Annemiek Broijl, Wilfried W. H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H. J. van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Wida Razawy, Paola Tacchetti, Katia Mancuso, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hajek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto
Summary: The EMN12/HOVON-129 study aimed to improve the prognosis of patients with primary plasma cell leukemia by incorporating carfilzomib and lenalidomide in their treatment. The results showed a significant improvement in progression-free survival compared to previously published data. However, the prognosis of primary plasma cell leukemia remains inferior to that of multiple myeloma.
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Medicine, General & Internal
Pablo R. Kappen, M. Mos, Johannes Jeekel, Clemens M. F. Dirven, Steven A. Kushner, Robert-Jan Osse, Michiel Coesmans, Marten J. Poley, Mathijs S. van Schie, Bronno van der Holt, M. Klimek, Arnaud J. P. E. Vincent
Summary: A prospective randomized controlled trial found that playing preferred music before, during, and after neurosurgery can reduce the risk of delirium after craniotomy, but this effect was not significant when using the DSM-5 diagnostic criteria. Music also increased heart rate variability. The validation of delirium screening tools and evaluation of long-term implications after craniotomy are needed.
Letter
Hematology
Mehmet Kemal Samur, Anil Aktas Samur, Jill Corre, Romain Lannes, Parth Shah, Kenneth Anderson, Herve Avet-Loiseau, Nikhil Munshi
Letter
Hematology
Kazimierz Groen, Fredrik H. Schjesvold, Bronno Van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen Van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. Van de Donk, Pieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman
Letter
Hematology
Kazimierz Groen, Fredrik H. Schjesvold, Bronno van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. van de Donk, Pieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman
Article
Oncology
Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Sonja Zweegman, Marc S. Raab, Markus Munder, Lucia Pantani, Katia Mancuso, Peter Brossart, Meral Beksac, Igor W. Blau, Jan Duerig, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Haenel, Ivana von Metzler, Ullrich Graeven, Carsten Mueller-Tidow, Mario Boccadoro, Christof Scheid, Meletios A. Dimopoulos, Jens Hillengass, Katja C. Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt
Summary: This study examines the incidence and causes of morbidity and mortality during induction therapy for newly diagnosed multiple myeloma (NDMM). It develops and validates a predictive risk score to identify NDMM patients at risk of severe infections or death. The study identifies four major risk factors and stratifies patients into low, intermediate, and high-risk groups. The risk score is validated in multiple trials incorporating quadruplet induction therapies.
Article
Oncology
Renske Gahrmann, Marion Smits, Rene Michel Vernhout, Walter Taal, Giorgios Kapsas, Jan Cees de Groot, Monique Hanse, Maaike Vos, Laurens Victor Beerepoot, Jan Buter, Zwenneke Hendrieke Flach, Bronno van der Holt, Martin van den Bent
Summary: This study investigated the optimal volumetric threshold for determining progressive disease in recurrent glioblastoma and found that early appearing new lesions were associated with poor overall survival. Lowering the volumetric threshold improved survival prediction, but led to a minimal increase in the number of patients classified as progressive disease.
NEURO-ONCOLOGY ADVANCES
(2022)
Article
Hematology
Ruth Wester, Avinash G. Dinmohamed, Bronno van der Holt, Sonja Zweegman, Monique Minnema, Sandra Croockewit, Mark-David Levin, Eduard Libourel, Esther de Waal, Pieter Sonneveld, Jan Cornelissen, Nicole Blijlevens, Annemiek Broijl
Summary: This nationwide, population-based registry study confirms the efficacy of pomalidomide combined with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma, with results comparable to those observed in pivotal clinical trials.